GSK presents new data showing that its asthma drug Nucala can significantly improve quality of life and lung function in patients with severe, eosinophilic form of asthma. The Phase IIIb MUSCA study had met all its primary and secondary endpoints successfully, showing that when the treatment was added to standard of care, patients experienced significant
Adaptimmune Therapeutics and GlaxoSmithKline have expanded the terms of their strategic collaboration agreement, with the aim to run clinical trials of Adaptimmune’s potential immunotherapy as a treatment for one of the rarest soft tissue cancers in the world.
GlaxoSmithKline (GSK) have confirmed that they are trying to compress the clinical trials of their potential Ebola vaccine into just 12 months. Normally it could take up to ten years to run clinical trials, with it typically taking 6 to 11 months to move an experimental vaccine from preclinical testing into clinical trials. However, due
David Willetts, the UK’s Science Minister, yesterday announced an investment of £52 million for the UK’s science sectors to improve skills and vocational training. The announcement was made at the official launch of the Science and Industrial Partnership (SIP), which is being led by GlaxoSmithKline (GSK). The announcement is expected to create over ‘7,800 education
GlaxoSmithKline (GSK) and Theravance’s inhaled lung drug, Relvar, has been approved by Europe’s regulatory body to treat both asthma and chronic obstructive pulmonary disease (COPD). Relvar is a combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2 agonist (LABA) vilanterol, and is delivered through the Ellipta inhaler. The drug has already been approved
Advisors to the European Medicines Agency (EMA) have voted in support of approving GlaxoSmithKline/ Theravance’s Relvar Ellipta for both asthma and chronic obstructive pulmonary disease (COPD). The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has delivered a response recommending marketing authorisation for Relvar Ellipta, a combination of the inhaled corticosteroid fluticasone
GlaxoSmithKline’s (GSK) Tafinlar has been given the green light by the European Commission to be used as an oral treatment for unresectable or metastatic melanoma in adults with a BRAF V600 mutation. Tafinlar (dabrafenib) is an orally bioavailable inhibitor of BRAF, part of the pathway that regulates the normal growth and death of cells. Mutations
The European Medicines Agency (EMA) has granted GlaxoSmithKline’s (GSK) melanoma drug an accelerated review. The melanoma drug, a MEK inhibitor named trametinib, is requesting a European licence as both a monotherapy and in combination with their investigational BRAF inhibitor dabrafenib, for the medication of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
GlaxoSmithKline (GSK) has become the first big pharma company to support the AllTrials campaign, which intends to improve clinical trial transparency. The campaign, which is supported by Dr Ben Goldacre, Bad Pharma’s author, and Dr Fiona Godlee, BMJ editor, is pushing for registration of clinical trials and the disclosure of results and reports to help